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Abstract
Aims
The relationship between nonalcoholic fatty liver disease and incident metabolic syndrome
in metabolically healthy subjects is unknown. We aimed to investigate whether nonalcoholic
fatty liver disease is a predictor of future metabolic syndrome in metabolically healthy
subjects.
Materials and methods
Subjects who underwent health evaluation at least twice between 2009 and 2015 from the
National Health Insurance Service-National Sample Cohort in South Korea were included.
Patients without obesity who had no metabolic syndrome components were finally analyzed
(n = 28,880). The definition of nonalcoholic fatty liver disease was based on both the hepatic
steatosis and fatty liver indices. The incidence of metabolic syndrome, prediabetes/type 2
diabetes, hypertension, and dyslipidemia was compared between the subjects with and
without nonalcoholic fatty liver disease.
Results
The presence of nonalcoholic fatty liver disease was associated with a higher risk of incident
metabolic syndrome, prediabetes/type 2 diabetes, hypertension, and dyslipidemia in the
entire cohort (metabolic syndrome: adjusted hazard ratio, 2.10; 95% confidence interval,
1.18–3.71; prediabetes/type 2 diabetes: adjusted hazard ratio, 1.42; 95% confidence inter-
val, 1.06–1.90; hypertension: adjusted hazard ratio, 2.36; 95% confidence interval, 1.35–
4.12; dyslipidemia: adjusted hazard ratio, 1.49; 95% confidence interval, 1.07–2.06). A simi-
lar finding was observed in the age-, sex-, smoking status-, and body mass index-based 1:5
propensity score-matched cohort of 1,092 subjects (metabolic syndrome: adjusted hazard
ratio, 3.56; 95% confidence interval, 1.79–7.07; prediabetes/type 2 diabetes: adjusted haz-
ard ratio, 1.97; 95% confidence interval, 1.04–3.73; hypertension: adjusted hazard ratio,
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2.57; 95% confidence interval, 1.35–4.88; dyslipidemia: adjusted hazard ratio, 1.61; 95%
confidence interval, 1.12–2.32).
Conclusions
Nonalcoholic fatty liver disease is an early predictor of metabolic dysfunction even in meta-
bolically healthy populations.
Introduction
A bidirectional relationship between nonalcoholic fatty liver disease (NAFLD) and metabolic
disease has recently been highlighted [1–5]. NAFLD may induce metabolic dysfunction
through hepatic insulin resistance, chronic metabolic stressor production, and inflammatory
response caused by hepatokines and lipid accumulation [6,7]. Several observational studies
demonstrated that NAFLD precedes type 2 diabetes, hypertension, dyslipidemia, and meta-
bolic syndrome [8–10]. However, previous studies are limited in providing evidence as to
which condition comes first because NAFLD is usually accompanied with metabolic syndrome
components.
Recently, the presence of NAFLD has been reported to be associated with an increased risk
of metabolic dysfunction in patients with one or more metabolic syndrome components [11],
which raises the issue of whether NAFLD is indeed a surrogate of metabolic disease in a popu-
lation without metabolic syndrome. This issue is clinically relevant because NAFLD is com-
mon in the general population [12], and its association with cardiovascular risks not attributed
to metabolic dysfunction has been reported [13,14]. If NAFLD is a surrogate of metabolic dis-
ease even in those without any metabolic syndrome components, it will provide a basis for
starting an earlier intervention, such as stricter lifestyle modification.
In this regard, we hypothesized that the presence of NAFLD is an early phenotypic predic-
tor of future metabolic dysfunction in a metabolically healthy population. By applying simple
biochemical indices developed to predict the presence of NAFLD [15,16], we investigated the
impact of NAFLD on the development of metabolic disease in a truly metabolically healthy
population.
Materials and methods
Study design and participants
This study was based on the national health claims database provided by the National Health
Insurance Service (NHIS) of South Korea. The NHIS is a mandatory national insurance service
that covers more than 97% of all Koreans and provides biennial health examination to all par-
ticipants. For the current analysis, we included study participants from the NHIS-National
Sample Cohort (NHIS-NSC) version 2.0, which was updated from the NHIS-NSC in 2017 and
a representative cohort including 1,108,369 participants randomly extracted from the total
South Korean population. The detailed design and profile of the NHIS-NSC have been
described previously [17]. Each participant’s demographic characteristics, diagnoses, and pre-
scription records in both the inpatient and outpatient services are available in the NHIS-NSC.
The claim diagnoses are based on the International Classification of Disease-10th Revision-
Clinical Modification (ICD-10-CM) codes. The overall study was approved by the Seoul
National University Hospital institutional review board (E-1807-001-953). The need for
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informed consent was waived by the institutional review board as the information of the par-
ticipants used for the analysis was anonymized and unidentified. The study protocol was in
accordance with the ethical guidelines of the 1975 Declaration of Helsinki.
Study population
Participants aged�18 years who underwent health evaluation at least two times between Janu-
ary 2009 and December 2015 were included. The basis of including these participants was that
at least two health evaluations were needed after a baseline evaluation to make a diagnosis of
incident metabolic syndrome. To prevent potential bias by preceding cardiovascular events,
malignancy, and other liver diseases, we excluded those with a history of cerebrovascular dis-
ease (ICD-10-CM codes I60–I64), ischemic heart disease (ICD-10-CM codes I22–I23), periph-
eral artery disease (ICD-10-CM codes I70 and I73), end-stage renal disease (ICD-10-CM
codes N185 and Z49), any malignancy (ICD-10-CM codes C00–C97), and any liver disease
(ICD-10-CM codes K70–K77), alcoholics (�30 g per week), and those with positive hepatitis B
antigen findings in the baseline health evaluation. We finally included metabolically healthy
participants with non-obese body mass index (BMI, 18.5–24.9 kg/m2) after further excluding
those who had a history of type 2 diabetes (ICD-10-CM codes E11–E14) or anti-diabetic medi-
cation use, hypertension (ICD-10-CM codes I10–I15) or anti-hypertensive medication use,
dyslipidemia (ICD-10-CM codes E78 and its all sub-classifications) or lipid-lowering medica-
tion use, and sleep apnea (ICD-10-CM code G473) and no metabolic syndrome components
as defined using the National Cholesterol Education Program Adult Treatment Panel III crite-
ria [18,19] at baseline health evaluation (Fig 1).
Definition of NAFLD
The hepatic steatosis index (HSI) is a validated index used to predict the presence of NAFLD;
it has been found to have a high specificity and sensitivity in a large cohort of Koreans [15].
We divided the participants into two groups according to the HSI cutoff value of specificity
and sensitivity: NAFLD group: HSI of>36, indicating high probability of NAFLD and non-
NAFLD group: HSI of<30, indicating low probability of NAFLD. As the metabolically healthy
study participants are less likely to have NAFLD than the entire general population, we cross-
validated the presence of NAFLD using the fatty liver index (FLI), which is an index of proven
predictability for the presence of NAFLD in the European population [16]. We applied a sensi-
tivity cutoff FLI value of 30 to the group with an HSI of>36 to exclude false-positive HSI and
a specificity cutoff FLI value of 60 to the group with an HSI of<30 to test the rate of false-nega-
tive HSI. Among the total 1,061 participants with an HSI of>36, 182 participants were consid-
ered to have NAFLD after further excluding 879 participants who had a low FLI (defined as
false-positive HSI). As none of the participants with an HSI of<30 had a high FLI, a total of
28,698 participants were considered to have no NAFLD.
Primary and secondary endpoints
The enrollment date was defined as the date of each participant’s first health evaluation
between January 2009 and December 2014. The data cutoff date was December 31, 2015. The
primary endpoint was incident metabolic syndrome during follow-up. Metabolic syndrome
was defined using the National Cholesterol Education Program Adult Treatment Panel III cri-
teria [18,19]: three or more of the following five criteria: waist circumference of>90 cm in
men or>80 cm in women, blood pressure of>130/85 mmHg, fasting triglyceride (TG) level
of>150 mg/dL, fasting high-density lipoprotein (HDL) cholesterol level of<40 mg/dL in men
or<50 mg/dL in women, and fasting blood glucose level of>100 mg/dL.
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The secondary endpoints were incident prediabetes/type 2 diabetes, hypertension, and dys-
lipidemia. Incident prediabetes was defined as a serum fasting glucose level of>100 mg/dL at
follow-up health evaluation or a clinical diagnosis of prediabetes (ICD-10-CM code R73 or its
Fig 1. Flow chart and the selection of the study participants. FLI, fatty liver index; HSI, hepatic steatosis index; NAFLD, nonalcoholic fatty liver disease.
https://doi.org/10.1371/journal.pone.0224626.g001
Fatty liver and future metabolic diseases
PLOS ONE | https://doi.org/10.1371/journal.pone.0224626 November 4, 2019 4 / 15
all sub-classifications). Incident type 2 diabetes was defined as a clinical diagnosis of type 2 dia-
betes (ICD-10-CM codes E11–E14) or use of anti-diabetic medications. Incident hypertension
was defined as a clinical diagnosis of hypertension (ICD-10-CM codes I10–I15) or use of anti-
hypertensive medications and incident dyslipidemia as a clinical diagnosis of disorders of lipo-
protein metabolism and other lipidemias (ICD-10-CM code E78 and its all sub-classifications)
or use of lipid-lowering medications.
Statistical analysis
Categorical variables were shown as numbers (percentages) and continuous variables as
means ± standard deviations. The difference in the categorical variables between the groups
was assessed using the chi-square test and that in the continuous variables using one-way anal-
ysis of variance or the Kruskal-Wallis test as appropriate. P-values of<0.05 were considered
statistically significant. All analysis was performed using the R language version 3.4.3 (R Foun-
dation for Statistical Computing, Vienna, Austria).
We performed a propensity score matching analysis to focus on the effect of NAFLD on the
incidence of metabolic syndrome and to reduce the impact of differences in the demographics
between the NAFLD and non-NAFLD groups. The propensity of being in the NAFLD group
was calculated using a logistic regression model including age, sex, smoking status, and cate-
gory of BMI (normal or overweight). The NAFLD group and the non-NAFLD group were
matched at a ratio of 1:5 using the nearest-neighbor method without replacement, with a cali-
per of 0.01 of the propensity score. We applied univariate and multivariate standard Cox
regression models to test whether the presence of NAFLD is an early predictor of the primary
and secondary endpoints in the entire cohort and the propensity score-matched cohorts. In
the multivariate analysis, age, sex, smoking status, and the category of BMI (normal or over-
weight) were included in the Cox regression model. We also performed a subgroup analysis
based on age, sex, smoking status, and category of BMI (normal or overweight). A mediation
analysis was performed using a logistic regression model to verify the direct effect of NAFLD
on the primary and secondary endpoints.
Results
Baseline characteristics of the study participants
The baseline characteristics of the study participants before and after propensity score matching
are shown in Table 1. After application of the inclusion and exclusion criteria, there were a total
of 28,880 participants without obesity who had no metabolic syndrome components. At base-
line evaluation, the NAFLD group subjects were older and more likely to be men, current smok-
ers, and overweight. After 1:5 propensity score matching, a total of 1,092 patients were included
in the final analysis (NAFLD group: n = 182; non-NAFLD group: n = 910). Among the propen-
sity score-matched cohort, the mean age was 37.2 years and 37.4 years in the NAFLD and non-
NAFLD groups, respectively (P = 0.68). The proportion of male subjects, current smokers, and
overweight subjects was the same between the two groups. The total cholesterol, TG, HDL cho-
lesterol, and low-density lipoprotein cholesterol levels and blood pressure were all in the normal
range in both the NAFLD and non-NAFLD groups. Among the laboratory findings, only the
alanine transaminase level was higher than the normal range in the NAFLD group.
Higher incidence of metabolic syndrome in the NAFLD group
Among the entire metabolically healthy subjects (n = 28,880), the risk of incident metabolic
syndrome at the follow-up health evaluation was significantly higher in the NAFLD group
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than in the non-NAFLD group (unadjusted hazard ratio (uHR), 8.60; 95% confidence interval
(CI), 5.12–14.46, P<0.01; adjusted hazard ratio (aHR), 2.10; 95% CI, 1.18–3.71, P = 0.01). This
result was similar in the propensity score-matched cohort (uHR 2.76, 95% CI, 1.59–4.81, P<0.01;
aHR, 3.56; 95% CI, 1.79–7.07, P<0.01) (Table 2). The cumulative incidence of metabolic syn-
drome was significantly higher in the NAFLD group both before and after propensity matching
(log-rank P<0.01 for the unmatched cohort, S1 Fig; log-rank P<0.01 for the propensity score-
matched cohort, Fig 2A). The number and proportion of patients with each of the components of
metabolic syndrome in both the NAFLD and non-NAFLD groups at follow-up evaluation dem-
onstrated that the difference in the incidence of newly diagnosed metabolic syndrome between
them was mainly because of the development of abdominal obesity, hypertriglyceridemia, and
prediabetes (S1 Table). Although statistically insignificant, the proportion of subjects with
Table 1. Baseline clinical characteristics of study population before and after propensity score matching, according to presence of NAFLD.
Entire cohort (n = 28,880) Matched cohort (n = 1,092)
Non-NAFLD
(n = 28,698)
NAFLD
(n = 182)
p-value Non-NAFLD
(n = 910)
NAFLD
(n = 182)
p-value
Age (yrs) 36.0±10.9 37.4±8.9 <0.01 37.2±9.0 37.4±8.9 0.68
Male (n, %) 10237 (35.7) 167 (91.8) <0.01 835 (91.8) 167 (91.8) 1.00
BMI
Normal (n, %) 26782 (93.3) 8 (4.4) <0.01 40 (4.4) 8 (4.4) 1.00
Overweight (n, %) 1916 (6.7) 174 (95.6) <0.01 870 (95.6) 174 (95.6) 1.00
Current smoking (n, %) 5106 (17.8) 84 (46.2) <0.01 420 (46.2) 84 (46.2) 1.00
Waist circumference (cm)
Male 75.7±4.9 83.7±3.5 <0.01 79.8±4.2 83.7±3.5 <0.01
Female 68.4±4.5 77.1±1.6 <0.01 73.0±3.4 77.1±1.6 <0.01
Laboratory findings
ALT (IU/L) 14.0±7.4 58.0±39.8 <0.01 14.9±6.8 58.0±39.8 <0.01
AST (IU/L) 20.4±12.6 31.2±17.1 <0.01 23.4±13.7 31.2±17.1 <0.01
ALT/AST ratio 0.7±0.2 1.8±0.4 <0.01 0.7±0.1 1.8±0.4 <0.01
GGT (IU/L) 16.8±9.6 72.7±47.6 <0.01 20.3±9.3 72.7±47.6 <0.01
Total cholesterol (mg/dL) 180.3±29.6 204.8±33.8 <0.01 182.4±29.7 204.8±33.8 <0.01
Triglyceride (mg/dL) 72.7±27.2 116.8±21.2 <0.01 83.5±28.5 116.8±21.2 <0.01
LDL-cholesterol (mg/dL) 110.5±24.3 127.8±32.8 <0.01 109.7±44.9 127.8±32.8 <0.01
HDL-cholesterol (mg/dL) 63.7±19.7 53.9±9.3 <0.01 57.4±18.5 53.9±9.3 <0.01
Fasting blood glucose (mg/dL) 86.1±7.6 88.2±7.2 <0.01 86.4±7.6 88.2±7.2 <0.01
Systolic blood pressure (mmHg) 110.6±9.3 115.5±7.5 <0.01 113.8±8.3 115.5±7.5 0.01
Diastolic blood pressure (mmHg) 69.3±7.3 72.8±6.4 <0.01 71.6±6.9 72.8±6.4 0.06
Creatinine (mg/dL) 1.0±1.2 1.1±1.2 <0.01 1.2±1.3 1.1±1.2 0.24
Interval between baseline and follow-up evaluation (years) 1.8±1.0 1.7±1.1 0.09 1.7±1.0 1.7±1.1 0.53
Clinical event
Metabolic syndrome (n, %) 294 (1.0) 15 (8.2) <0.01 18 (2.0) 15 (8.2) <0.01
Prediabetes/Type 2 diabetes mellitus (n, %) 4581 (16.0) 49 (26.9) <0.01 158 (17.4) 49 (26.9) <0.01
Hypertension (n, %) 768 (2.7) 14 (7.7) <0.01 28 (3.1) 14 (7.7) <0.01
Dyslipidemia (n, %) 4362 (15.2) 38 (20.9) 0.04 122 (13.4) 38 (20.9) 0.01
Hepatic steatosis index 27.6±1.6 38.8±3.0 - 28.9±1.0 38.8±3.0 -
Fatty liver index 5.4±4.6 38.1±7.0 - 13.1±6.7 38.1±7.0 -
The data are presented as mean±SD for continuous variables and number (percentage) for categorical variables. ALT, alanine aminotransferase; AST, aspartate
aminotransferase; BMI, body mass index; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAFLD, nonalcoholic fatty
liver disease.
https://doi.org/10.1371/journal.pone.0224626.t001
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incident high blood pressure and low HDL cholesterol level at follow-up was also higher in the
NAFLD group. After propensity score matching, the proportion of participants without any meta-
bolic syndrome component at follow-up was still significantly lower in the NAFLD group than in
the non-NAFLD group (35.2% vs 55.9%, P<0.01); conversely, the proportion of participants with
two or more metabolic syndrome components was higher in the NAFLD group (S1 Table and
Fig 2B). The subgroup analysis also demonstrated that the effect of NAFLD on future metabolic
syndrome was irrespective of age, sex, smoking status, and BMI (Fig 2C).
Relationship between NAFLD and incident prediabetes/type 2 diabetes,
hypertension, and dyslipidemia
In the secondary endpoint analysis, the risk of incident prediabetes/type 2 diabetes, hyperten-
sion, and dyslipidemia was higher in the NAFLD group even after adjusting for age, sex, smok-
ing status, and BMI (aHR for prediabetes/type 2 diabetes, 1.42; 95% CI, 1.06–1.90, P = 0.02;
aHR for hypertension, 2.36; 95% CI, 1.35–4.12, P<0.01; aHR for dyslipidemia, 1.49; 95% CI,
1.07–2.06, P = 0.02). This result was similar in the propensity score-matched cohort (aHR for
prediabetes/type 2 diabetes, 1.97; 95% CI, 1.04–3.73, P = 0.04; aHR for hypertension, 2.57; 95%
CI, 1.35–4.88, P<0.01; aHR for dyslipidemia, 1.61; 95% CI, 1.12–2.32, P = 0.01) (S2 Table).
Among the entire cohort (n = 28,880), the cumulative incidence of prediabetes/type 2 dia-
betes, hypertension, and dyslipidemia was higher in the NAFLD group (S2 Fig). This result
was consistent in the propensity score-matched cohort of 1,092 subjects (Fig 3).
A sensitivity analysis was performed in all subgroups according to age, sex, smoking status,
and BMI. The trends for incident prediabetes/type 2 diabetes, hypertension, and dyslipidemia
were consistent in all subgroups, except for hypertension in the normal BMI group (which
could not be calculated because there were only a few subjects with normal BMI and NAFLD,
and none of these subjects developed hypertension on follow-up). There was a significant
interaction between the smoking status and incident prediabetes/type 2 diabetes and between
sex and incident dyslipidemia (S3 Fig). In the mediation analysis, NAFLD still showed a signif-
icant and direct effect on the incidence of metabolic syndrome, prediabetes/type 2 diabetes,
hypertension, and dyslipidemia, independent of the BMI.
Discussion
We investigated the impact of NAFLD on metabolic dysfunction in a population without obe-
sity and any metabolic syndrome components. We focused on the predictive impact of
Table 2. Univariate and multivariate Cox proportional-hazards regression analysis for incident metabolic syndrome in the entire cohort and the propensity score-
matched cohort.
Total cohort (n = 28,880) Matched cohort (n = 1,092)
Unadjusted Covariate-adjusted† Unadjusted
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
NAFLD 8.60 (5.12–14.46) <0.01 2.10 (1.18–3.71) 0.01 3.56 (1.79–7.07) <0.01
Age 1.04 (1.03–1.04) <0.01 1.03 (1.02–1.04) <0.01 1.01 (0.97–1.05) 0.60
Male 2.50 (2.00–3.13) <0.01 1.39 (1.06–1.84) 0.02 0.81 (0.24–2.66) 0.73
Body mass index 1.56 (1.45–1.69) <0.01 1.40 (1.29–1.53) <0.01 1.04 (0.14–7.62) 0.97
Current smoking 2.20 (1.74–2.84) <0.01 1.60 (1.20–2.14) <0.01 1.29 (0.65–2.55) 0.47
Cox proportional-hazards regression analysis to identify predictors of incident metabolic syndrome at follow-up health evaluation.
†, adjusted for NAFLD, age, male, body mass index, current smoking.
CI, confidence interval; HR, hazard ratio; NAFLD, non-alcoholic fatty liver disease.
https://doi.org/10.1371/journal.pone.0224626.t002
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NAFLD on future incident metabolic syndrome, in isolation from other metabolic confound-
ers. By employing a large general population cohort and non-invasive validated indices to pre-
dict the presence of NAFLD, we demonstrated that NAFLD is an early phenotypic predictor of
metabolic syndrome, prediabetes/type 2 diabetes, hypertension, and dyslipidemia in a meta-
bolically healthy population. Our results support the concept that NAFLD is not a mere indica-
tor of accompanying metabolic syndrome components but has an independent predictive
value for future metabolic syndrome.
Fig 2. NAFLD as an independent early predictor of incident metabolic syndrome. (A) Cumulative incidence of metabolic syndrome in the propensity score matched
cohort, according to the presence of NAFLD. (B) Proportion of patients with each number of metabolic syndrome components at follow-up health evaluation,
according to the presence of NAFLD. (C) Subgroup analysis of incident metabolic syndrome. BMI, body mass index; CI, confidence interval; HR, hazard ratio; NAFLD,
nonalcoholic fatty liver disease.
https://doi.org/10.1371/journal.pone.0224626.g002
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Relationship between NAFLD and metabolic dysfunction
We showed the association of NAFLD with metabolic dysfunction, starting from a metaboli-
cally healthy status. In addition to several studies reporting a possible bidirectional relationship
between NAFLD and metabolic syndrome [20–24], we provide more strict evidence on
NAFLD as an early phenotypic predictor of metabolic dysfunction.
Insulin resistance in adipose tissues, the muscles, and the liver with excessive free fatty acids
plays a central role in the development of metabolic syndrome [25]. In this aspect, the liver
acts as the site of insulin resistance caused by the overflow of circulating fatty acids. Otherwise,
the concept that fat deposition in the liver also contributes to hepatic insulin resistance by the
activation of enzymes that impair hepatic insulin signaling [26] and by the altered adipokine
secretion in subjects with NAFLD [6] has been suggested. This mechanism could explain our
finding of why subjects with intrahepatic fat disposition but without clear evidence of known
metabolic syndrome components have a higher incidence of metabolic syndrome. Therefore,
NAFLD could be an early surrogate of metabolic disease or a separate disease entity.
NAFLD occurs upstream during type 2 diabetes development
A high prevalence of prediabetes/type 2 diabetes and increased insulin resistance in patients
with NAFLD have been reported [27,28]. Even among euglycemic patients, the incidence of
type 2 diabetes was higher in those with NAFLD than in those without [29]. As for the relation-
ship between NAFLD and type 2 diabetes, the direction from NAFLD to type 2 diabetes has
recently been highlighted in a meta-analysis [8], and the improvement of NAFLD was associ-
ated with the reduction of the rate of incident type 2 diabetes [30].
Similar with previous findings, NAFLD was a significant predictor of prediabetes/type 2
diabetes preceding the development of any metabolic syndrome components in the current
study. This suggests that NAFLD is not a mere marker of other shared risk factors in the devel-
opment of type 2 diabetes but could be involved at the upstream of the developmental cascade
of type 2 diabetes. NAFLD may be considered as a surrogate or a possible driver for the pro-
gression to prediabetes/type 2 diabetes, although the onset of prediabetes/type 2 diabetes and
its relationship with NAFLD may be different among individuals. This result warrants regular
screening for prediabetes/type 2 diabetes and early interventions, such as lifestyle modifica-
tion, in patients with NAFLD even if they do not have any metabolic derangements.
NAFLD without metabolic dysfunction still predicts future hypertension
Patients with NAFLD had a higher incidence of hypertension than those without NAFLD in
several prospective studies [9,31,32]. This is mainly explained by hepatic insulin resistance
Fig 3. NAFLD as a possible surrogate of metabolic dysfunction. Cumulative incidence of (A) prediabetes/type 2 diabetes, (B) hypertension, and (C) dyslipidemia in
the propensity score matched cohort, according to the presence of NAFLD. NAFLD, nonalcoholic fatty liver disease.
https://doi.org/10.1371/journal.pone.0224626.g003
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contributing to endothelial dysfunction and vasoconstriction [33]. In recent studies, the
hepatic insulin resistance index correlated with the risk of incident hypertension [34]. Addi-
tionally, NAFLD is known to induce dysregulation of the renin-angiotensin-aldosterone sys-
tem in animal models [2], leading to arterial hypertension.
Despite the clear association of NAFLD with hypertension in prospective studies and its
pathophysiological mechanism, it has been difficult to dissect the lone impact of NAFLD on
the development of hypertension because NAFLD is accompanied by metabolic dysfunction.
Our study is one of the first studies to demonstrate that NAFLD is a significant predictor of
future development of hypertension even without overt metabolic dysfunction. Physicians
should be proactive in monitoring for the development of hypertension when treating a nor-
motensive subject with NAFLD.
Reciprocity between NAFLD and lipid metabolism
In general, NAFLD is mainly caused by altered lipid metabolism with increased systemic lipol-
ysis that leads to increased uptake of free fatty acids in and decreased TG export from the liver
[35]. After the development of NAFLD, intrahepatic lipid accumulation potentiates further
alteration in lipid metabolism, which induces a vicious cycle [35].
In the present study, we proved that “the vicious cycle” could be initiated from NAFLD
first, indicating that NAFLD is a predictor of future dyslipidemia. Furthermore, NAFLD has
been demonstrated to be associated with decreased levels of circulating HDL2 cholesterol, one
of the HDL cholesterol subfractions, and increased levels of small, dense low-density lipoprotein
cholesterol, both of which are proatherogenic lipid subtypes [36–38]. Therefore, NAFLD should
be regarded as one of the risk factors for the aggravation of lipid profiles independent from tra-
ditional risk factors, and the association of NAFLD with dyslipidemia might serve as a link
between NAFLD and future clinical vascular event by inducing proatherogenic dyslipidemia.
Significant impact of NAFLD in the patients with low metabolic risks
In the subgroup analysis, female sex was associated with a higher likelihood of metabolic dys-
function. This tendency was also shown in a previous observational study [39]. The result of
our study indicates that NAFLD in women should be considered as an equally strong or even a
stronger risk factor for metabolic dysfunction, although it is traditionally more prevalent in
men. Further investigations as to whether there are sex differences in the prognosis, especially
of patients with incident cardiovascular diseases and NAFLD, are warranted, considering that
its significance has rarely been discussed.
Furthermore, the condition of the patients with NAFLD with low metabolic risks, such as
young age, non-smoking status, and normal BMI, tended to progress more towards metabolic
dysfunction. The primary etiology of NAFLD in the low metabolic risk subgroup may include
genetic predisposition because the study population had none of the traditional metabolic risk
factors. Indeed, there have been efforts to identify both common and rare genetic variants that
could explain the development of metabolic syndrome [40]. Therefore, the higher probability
of metabolic dysfunction in the low metabolic risk subgroup might indirectly indicate the
effect of certain genetic variants on NAFLD, leading to a more rapid disease progression [41].
Limitations
This study has several limitations. First, although both the HSI and FLI are well-known nonin-
vasive validated indices in the prediction of NAFLD, diagnosis mainly based on these bio-
chemical indices might lead to a certain rate of false-negative or -positive findings. Some
limitation of the FLI has also been reported [42], and we did not include ultrasonographic
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findings in the diagnosis of NAFLD. However, the study populations were limited to subjects
without obesity with normal waist circumference, which means that the high scores in both
indices were obtained mainly owing to the elevated alanine transaminase and GGT levels. We
further excluded heavy drinkers and those with a diagnosis of any liver disease; therefore, it
would be difficult to consider a differential diagnosis for the elevation of liver enzyme levels
other than NAFLD. Second, the definitions of the outcomes were mainly based on the diag-
nostic codes, which is an inherent limitation of the study using a claims database. It might
cause misclassification or underestimation; however, the methodology based on claims data
has been validated in previous studies [43,44]. Third, other metabolic confounders were not
included in this analysis. Although detailed family history and additional measurements, such
as waist-to-hip ratio or insulin resistance, could make our findings more generalizable, the
effect size of the potential confounders would be small because our study population had none
of the components of metabolic syndrome and no obesity. Fourth, the extrapolation of the
study findings to different ethnic groups may be limited and warrants further investigation in
non-Asian populations. Lastly, although the impact of NAFLD according to sex should be con-
sidered separately [45], we could not fully analyze the effect according to sex separately owing
to the small number of female NAFLD subjectsincluded. This may lead to potential bias,
which cannot be adjusted by the multivariate analysis or subgroup analysis performed in the
present study. Further, the reproductive status, an important factor for the effect of NAFLD
[46], was not accounted for owing to data unavailability in the database.
Conclusions
In the current study, we demonstrated that NAFLD is an early phenotypic marker predictive
of future metabolic disorders. Along with its pathophysiological role regarding insulin resis-
tance in metabolic disorders, NAFLD should be considered as an independent surrogate or
even a disease that is associated with future metabolic dysfunction and not a mere hepatic
manifestation of metabolic disorders. Our analysis also suggests a possible link between
NAFLD and cardiovascular events observed in previous studies [13,14,35]. These results indi-
cate the need for early screening for metabolic disease and earlier planning of therapeutic
intervention for patients with NAFLD, which might lead to a reduction of the incidence of car-
diovascular diseases caused by metabolic disease with NAFLD in the long term.
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